AgBiome Pitch Deck: All 14 Slides + Teardown

AgBiome’s Series D deck is a clinical example of how to present a 'platform-plus-product' story to late-stage investors. By 2021, the company had moved beyond theoretical science to commercial reality, citing significant revenue from its first product, Howler. The deck leverages a high-pedigree team—featuring former CEOs of Bayer and GE—and a proprietary database of over 90,000 sequenced microbes to justify a massive $116M raise. It successfully balances the immediate commercial traction of its current fungicides with a long-term roadmap of 30 product launches by 2030. While it lacks specific…

Key takeaways

• The team slide (Slide 3) features heavyweights like Marijn Dekkers (former CEO of Bayer) and John Flannery (former CEO of GE), providing immense institutional credibility.
• AgBiome positions its 'Genesis' platform as a data science moat, claiming a collection of 90,000+ sequenced microbes and 300M+ unique genes (Slide 5).
• The market slide (Slide 7) projects the global biologicals market to grow from $1.4B in 2020 to $14.4B by 2030, a 10x increase in one decade.
• A detailed product roadmap (Slide 9) promises a rapid scaling from 1 product launch in 2020 to 30 cumulative launches by 2030.
• The company employs four distinct business models—ranging from wholly-owned to late-stage licensing—to maximize revenue streams across different market segments (Slide 11).
• Traction is validated through ~240 product demos and the claim that their first product, Howler, generated significant revenue in its first full year (Slide 13).
• The deck emphasizes exit potential by listing six major industry acquisitions since 2019, including Syngenta’s acquisition of Valagro (Slide 7).
• Despite the $116M raise, the deck does not include a specific 'Ask' slide or a detailed breakdown of how the Series D capital will be allocated.

Frequently asked questions

What is AgBiome's core technology?

AgBiome's core technology is the Genesis platform, described on Slide 5. It is a microbial discovery engine that has sequenced over 90,000 microbe strains and identified over 300 million unique genes. This allows the company to use custom machine learning to compare 45,000 genomes per second, significantly accelerating the discovery of natural, non-chemical pesticides and crop protection solutions.

How does AgBiome generate revenue?

As shown on Slide 11, AgBiome uses four business models: Wholly-Owned (direct revenue/profit), JV/In-License (royalties and profit sharing), Early License (upfront cash and royalties), and Late License (milestones and pipeline monetization). This multi-pronged approach allows them to capture value from their platform while partnering with giants like Elanco and TMG for specific market access.

What is the market opportunity for biological pesticides?

According to Slide 7, the global biologicals market is expected to grow from $1.4 billion in 2020 to $14.4 billion by 2030. During this same period, the market share of biologicals relative to traditional chemicals is projected to rise from 2% to 14%, driven by regulatory concerns and increasing pest resistance to synthetic chemicals.

Who are the key people behind AgBiome?

The leadership team (Slide 3) includes Co-CEOs Scott Uknes and Eric Ward, both with decades of experience in AgTech. The board is particularly notable, featuring Marijn Dekkers, the former CEO of Bayer and Thermo Fisher Scientific, and John Flannery, the former CEO of GE. This level of executive experience is rare for a startup and signals high institutional confidence.

What products does AgBiome currently have in the market?

The deck highlights 'Howler' as their flagship biological fungicide, which generated significant revenue in its first year (Slide 13). Slide 9 shows 'Theia' as a subsequent launch in the biological fungicide category, with a broader pipeline of insecticides, herbicides, and biostimulants scheduled for release through 2030.

AgBiome pitch deck: the facts

Company

AgBiome

Year

2021

Stage

Series D

Slides

14

Sector

Agriculture / Biotechnology

Deck type

Investor Pitch Deck

Outcome

$116M Raised

Headquarters

North America

AgBiome pitch deck PDF

The full AgBiome deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the AgBiome pitch deck was used for

This is AgBiome’s Series D pitch deck from 2021, a 14‑slide presentation used to raise $116M for its biological crop protection platform and products.[1][2][4][5] The deck positions AgBiome as a leader in microbe‑based crop protection, built around a large fully sequenced microbial collection and the GENESIS proprietary data science platform.[1][5][12][15] It focuses on sustainable, naturally derived fungicides such as Howler and pipeline traits, framed as alternatives to synthetic chemical pesticides in global agriculture.[1][4][5][9][15] The raise was for scaling commercial crop protection products, expanding the microbial platform, and advancing R&D for additional biologicals and traits.[1][2][4][5]

Business model: AgBiome is a biotechnology company that discovers and develops biological and trait-based crop protection products by leveraging the plant-associated microbiome and proprietary data science to identify microbes with fungicidal, insecticidal, and nematicidal activity.[1][7][9][12][15]

Round

Series D[1][2][4][5][10][13]

Lead investor

Blue Horizon and Novalis LifeSciences co‑led the Series D round.[1][2][4][5][8][13]

Investors

Blue Horizon (co‑lead)[1][2][3][4][5][13], Novalis LifeSciences (co‑lead)[1][2][4][5][8][13], Bayer (participant)[3], Fidelity (participant)[3], UTIMCO – University of Texas/Texas A&M Investment Management Company (participant)[3], The Mosaic Company (participant)[3], Polaris Partners (participant)[3][6], ARC (participant)[3]

Founded

2012[9]

Founders

Scott Uknes, Eric Ward, Jeff Dangl, John Ryals, Paul Schulze-Lefert[9]

Headquarters

Research Triangle Park, North Carolina, United States[4][11][15]

Industry

Agricultural biotechnology / biological crop protection[1][7][9][12][15]

Year: 2021[1][2][4][5][10][13]

Raised: $116M Series D funding round announced in September 2021.[1][2][4][5][10][13]

Total funding: Approximately $230M–$233M total funding as of the 2021 Series D round, including the $116M Series D.[2][5][8][13]

Use of funds as presented: To expand AgBiome’s microbial discovery platform and GENESIS data science, advance its pipeline of biological and trait-based crop protection products, and scale commercial execution for sustainable fungicides and related solutions.[1][2][4][5][7][9][10][12][15]

What happened after the AgBiome deck

After raising a $116M oversubscribed Series D in September 2021 led by Blue Horizon and Novalis LifeSciences, AgBiome continued to expand its microbial platform and commercial portfolio, including fungicides such as Howler and Theia and later Howler EVO, while pursuing broader global deployment of biological crop protection solutions.[1][2][4][5][7][9][10][14][15]

• By late 2021, AgBiome had increased total funding to roughly $230M–$233M following the $116M Series D round.[2][5][8][13
• AgBiome advanced commercialization of its first fungicide Howler for broad disease control across diverse crops.[7][9][1
• Subsequent product developments included Theia fungicide and later an evolved product Howler EVO, indicating continued p

What the AgBiome deck got right

• Differentiated microbial discovery and data science platform. The deck highlights AgBiome’s fully sequenced microbial collection and GENESIS proprietary data science platform, claiming the ability to compare over 100,000 strains in hours and analyze more than 300 million unique genes, which supports a differentiated discovery engine for biological crop protection.[1][5][7][12]
• Existing commercial fungicide products with broad agronomic applicability. AgBiome already has commercial products such as the Howler biological fungicide, with strong performance across numerous disease complexes and crop–disease combinations, demonstrating that the platform has translated into marketable solutions, not just research.[1][8][9][14][15]
• Compelling alignment with structural shifts toward sustainable agriculture. The deck situates AgBiome within major macro trends: growing global population, declining arable land, soil damage from chemicals, consumer demand for clean food, and regulatory pressure on synthetic pesticides, framing a large and durable opportunity for sustainable crop protection.[1][4][6][15]
• Focus on real-world ROI and strategic partnerships. The company emphasizes real‑world ROI and transformational partnerships to expand the reach of its microbial platform, suggesting a focus on commercial execution and collaboration with industry players, backed by strategic investors from ag and life sciences.[1][2][3][4][5][9][13]
• Clear ESG and UN SDG narrative around reduced chemical use and responsible food production. AgBiome connects its mission and products to ESG themes and UN Sustainable Development Goals, positioning its biological crop protection solutions as contributing to reduced chemical use, improved health, and sustainable food systems—appealing to impact investors.[1][4][12][15]

What could have been stronger

• Platform scale claims lack external benchmarks. The deck emphasizes having the “largest fully sequenced microbe collection” and “>300M unique genes” but provides no clear comparative benchmarks or third‑party validation to substantiate these superlative claims versus other microbial platforms.[1][5][12]
• Limited quantified, large-scale agronomic and commercial traction. While Slide 8 lists strong performance across many disease complexes and describes a case study from a North Carolina grower, the deck does not show systematic multi‑location trial data, adoption metrics, or yield/ROI quantification at scale for products like Howler.[1][8][9][15]
• ESG impact framed broadly without measurable indicators. The ESG slide claims alignment with 12 of 17 UN Sustainable Development Goals but does not map specific products or metrics (e.g., reduced chemical use, improved yields) to particular SDGs, which may make the impact narrative feel high level rather than evidence-based.[1]
• Regulatory and market access risks not clearly addressed. Although the deck states that AgBiome addresses grower and consumer demands for clean and safe food and reduces chemical impacts worldwide, it does not discuss regulatory pathways, registration status by region, or barriers to scaling biological crop protection in different markets.

How an investor would read this deck

What draws attention

• Evidence that the microbial platform genuinely offers a defensible edge in discovering active strains, including any third‑party comparisons or partnerships validating GENESIS and the fully sequenced microbe collection.[1][5][12]
• Commercial performance of Howler and subsequent products (e.g., acres treated, repeat purchase rates, pricing, and grower ROI) relative to synthetic fungicides and other biological competitors.[1][8][9][14][15]
• Regulatory approvals, registration timelines, and any region‑specific barriers to introducing biological fungicides and trait products globally.
• Strength of IP around microbial strains, data science methods, and formulation technologies and how this protects the platform from fast followers.[1][5][12]
• Quality and durability of relationships with strategic investors and potential distribution partners in crop protection and ag inputs.[1][2][3][4][13]

Risks that stand out

• Biological fungicides and traits depend on complex interactions with plant microbiomes and environmental conditions, creating variability in field performance that could limit adoption if products do not consistently match synthetic alternatives.[9][12][15]
• Regulatory frameworks for biological crop protection can be evolving and region‑specific; delays or unexpected requirements in key markets could slow commercialization and revenue growth.
• Competition from both established agrochemical companies and emerging biologicals firms may erode AgBiome’s claimed advantage in microbial collections and data science if rivals scale similar platforms.[7][9][12][14]
• Achieving meaningful ESG and UN SDG impact hinges on large‑scale replacement of conventional pesticides; if growers adopt AgBiome products primarily as supplements rather than replacements, the environmental impact narrative may be diluted.[1][4][15]

Questions this deck invites

• What specific quantitative performance data (yield increases, disease control percentages, reduction in chemical applications) from independent or multi‑location trials support the claims of “excellent” or “good” disease control across the
• How does AgBiome’s GENESIS platform compare technically and economically to other microbial discovery and screening platforms in terms of cost per candidate, discovery timelines, and hit rates for commercialisable strains?[1][5][12]
• What is the current and projected revenue, margin structure, and unit economics for products like Howler and Theia, and how sensitive are they to changes in chemical fungicide prices and regulatory regimes?[7][9][14][15]
• What are the key regulatory milestones and registration statuses for AgBiome’s biological products in its target markets (US, EU, other regions), and what risks exist around regulatory changes for biologicals?
• How are the proceeds from the $116M Series D allocated among platform R&D, product registration, manufacturing scale‑up, and commercial go‑to‑market, and what milestones were set with lead investors Blue Horizon and Novalis LifeSciences?[1]

What founders can take from the AgBiome deck

• A clearly articulated technology thesis anchored in a proprietary platform (in this case, a fully sequenced microbial collection and the GENESIS data science engine) can make a complex biotech story more investable when tied directly to product outcomes.[1][5][12]
• Connecting product performance (disease control across many pathogens and crops) to real‑world grower case studies helps bridge the gap between laboratory data and commercial relevance in agriculture pitch decks.[1][8][9][15]
• Framing the market problem broadly—soil damage from harsh chemicals, consumer demand for clean food, regulatory pressure on synthetics—can position biological crop protection as part of long‑term structural change, not a niche trend.[1][4][6][15]
• Explicitly linking a company’s mission and products to ESG themes and UN Sustainable Development Goals can resonate with impact‑oriented and long‑horizon investors, even if further detail is needed on metrics.[1][4][15]
• Highlighting both current commercial products (like Howler) and a pipeline of traits and biologicals shows investors near‑term revenue potential alongside longer‑term platform optionality.[1][5][7][9][14]

AgBiome pitch deck: common questions

What does AgBiome do?

AgBiome is a biotechnology company based in Research Triangle Park, North Carolina that develops biological and trait-based crop protection products from plant-associated microbes to provide sustainable alternatives to synthetic pesticides.[1][4][7][9][11][12][15]

How much did AgBiome raise with this Series D pitch deck, and who led the round?

In September 2021, AgBiome raised $116 million in an oversubscribed Series D funding round to expand its microbial platform and scale biological crop protection products.[1][2][4][5][10][13] The round was co-led by Blue Horizon and Novalis LifeSciences and brought the company’s total funding to roughly $230M–$233M.[1][2][4][5][8][13]

What products does AgBiome sell or plan to sell?

AgBiome’s commercial focus includes biological fungicides such as Howler, a broad-spectrum fungicide for a wide variety of crops, with Theia as a complementary fungicide expected to launch around 2021.[7][9][14][15] The pitch deck also highlights a pipeline of novel biologicals and traits built from its microbial platform.[1][5][9][12]

What is unique about AgBiome’s technology and platform according to the deck?

AgBiome’s value proposition is that its fully sequenced microbial collection and GENESIS data science platform allow rapid comparison of over 100,000 strains and analysis of hundreds of millions of unique genes to find highly active strains for crop protection.[1][5][7][9][12] This leads to sustainable fungicides and traits that can reduce reliance on harsh chemical pesticides while delivering real-world ROI to growers.[1][4][5][9][15]

What was AgBiome raising money for in the 2021 Series D round?

The Series D capital was raised to fund AgBiome’s expansion of its microbial platform, advance R&D and its pipeline of biologicals and traits, and scale commercial execution in crop protection through its subsidiary selling products like Howler.[1][2][4][5][7][9][10] The deck frames this as enabling global impact, reduced chemical use, and progress against UN Sustainable Development Goals.[1][4][5][12][15]

Sources

Funding and outcome facts on this page were researched on 2026-08-30 from the pages below.

• AgBiome Raises $116 Million Led By Blue Horizon and Novalis ...
• AgBiome cultivates $116m series D - Global Venturing
• AgBiome: Revenue, Competitors, Alternatives - Growjo
• AgBiome, agtech startup in RTP, NC, raises $116M Series D
• This startup created a natural alternative to chemical pesticides. Check out the pitch deck crop cleaner AgBiome used to raise $116 million.
• AgBiome - $120M Series D - Startup Intros
• AgBiome Company Overview, Contact Details & Competitors
• AgBiome cultivates $116m series D -

AgBiome pitch deck slides

What each slide of the AgBiome pitch deck says

Slide 3

s polaris ; J ARCH VENTURE ScoTT UKNES ERIC WARD Toni Bucci GERALD COWARD \ v NE Co-CEO Co-CEO Commercial Director, COO CFO PRRTIFAX Co-founder of multiple 30+ yearsinAg pr, Demin emorprotadion AGTECH®# successful Ag companies and CEO experience forAg companies N VA LIS of i 2BLADES Driscoltt § S | Jill prin cropsoton 4, unre O-BASF riscotts SP Uressinces Fidelity _ 47, X wl An novezymes ls : 4 BILLEMELINDA GATES RODRIGO SARRIA DAN Tomso MARIN DEKKERS JOHN FLANNERY 4] Research Business Development Chairman of the Board Benes or syngenta BAYER Scientific, Chairman Novalis LifeSciences - SN ST» 0:BASF Mhenix ~gvaLis ThermoFisher “5 (5¢) Innotech i Advisors Proprietary & Confidential | 3

Slide 4

AGBIOME COMPANY OVERVIEW & THESIS Innovating naturally derived crop protection products that enhance the global food production process and feed the world responsibly BEST-IN-CLASS BIOLOGICAL PRODUCTS WITH GLOBAL IMPACT MICROBIAL PLATFORM REAL-WORLD ROI Largest fully sequenced microbe collection Commercial execution in crop protection Addressing grower and consumer with unmatched informatics capability: Pipeline of novel biologicals and traits demands for clean & safe food 90Kto IMin3yrs Transformational partnerships to expand Reducing impact of chemicals worldwide Most advanced, growing pipeline of traits reach of microbial platform Enhancing safety of people, animals and biologicals targe…

Slide 5

THE CORE OF AGBIOME — AN INDUSTRY-LEADING (il MICROBIAL PLATFORM AgBiome was the first company in the world to sequence every strain they collected, allowing the development cuttingedge informatics tools to analyze genomes - The result is more highly active strains, innovative commercial products, and disruptive technologies with numerous applications UNPARALLELED MICROBIAL INSIGHTS AND APPROACHES Largest Microbe Collection 1012 90,000+ v' ABILITY TO COMPARE >100,000 STRAINS AT ONE TiME IN HOURs, NoT DAYs GENESIS™ PROPRIETARY DATA SCIENCE: >300M UNIQUE GENES Novel Wriormatics Fully-integrated, Trillions of Systematic, DataMicrobes Driven Screening Process Every Gene Z in Every [=X Most Micr…

Slide 6

WHY BIOLOGICAL CROP PROTECTION? TODAY'S SOLUTIONS ARE NOT WORKING Growing need for sustainable crop protection * Worldwide population Increasing, more mouths to feed * Arable land is declining, accelerated by soil damage from harsh chemicals * Farmers pressured by pest & crop resistance to synthetics: Less than 5% of market uses organic alternatives * Consumers demanding clean, healthy food * Long-term growth trend seen in organic produce consumption * Regulators seeking alternatives to synthetics Huge opportunity for Crop Protection # Hormtul Poisons Shunned Elsewhere Account for Quarter of All US. Pesticide Use New Study: United States Uses 85 Pesticides Outiawed in Other Countries. PORTL…

Slide 8

OUR FIRST APPLICATION - SUSTAINABLE AND EFFECTIVE BIOLOGICAL CROP PROTECTION UNTREATED Works on 4 300+ cropdisease combinations DISEASE COMPLEX PPERFORMANCE BoTRYTIS EXCELLENT CONTROL " RHIZOCTONIA EXCELLENT CONTROL COLLETOTRICHUM EXCELLENT CONTROL ALTERNARIA Goop CoNTRoL PYTHIUM Goop CNTROL /7 PHYTOPHTHORA (SOIL) Goop CONTROL <7 POWDERY MILDEWS Goop CONTROL <7 DOWNY MILDEWS. Goop CoNTROL 3 T A Conttacel DEMONSTRATED RESULTS + Non-organic NC grower with 300 acres of vegetables for restaurants « Squashfield with Pythium root rot + Decreased die-off after transplant, increased plant vigor, faster flowering and ripening Proprietary & Confidential 8

Slide 12

COMMITTED TO ESG AND ADDRESSING GLOBAL SUSTAINABLE DEVELOPMENT GOALS Addresses 12/17 UN Sustainable Development Goals - N GOODHEALTH QuALTY @ AND WELLBEING EDUCATION SUSTAINABLE GENDER EQUALITY DECENT WORK AND [ECONOMIC GROWTH 17 PARTNERSHIPS FOR THE GOALS & Proprietary & Confidential 12

Slide text above is read directly from the AgBiome deck PDF embedded on this page.

Related fundraising guides (24)

• FX HedgePool Pitch Deck Teardown: Disintermediating the $66 Trillion FX Swap Market
• Leonardo.ai Pitch Deck Teardown: A Product-First Showcase of Generative AI Traction
• Hedra Pitch Deck Teardown: A $32M Series A Built on Capital-Efficient AI Research
• BetterManager Pitch Deck Teardown: A $16M Series A Built on Traction and Google Pedigree
• Cube Pitch Deck Teardown: A $30M Series B Masterclass in Narrative Simplicity
• Handly Pitch Deck Teardown: A B2B2C Play for the €5 Trillion Craft Services Market
• Heali Pitch Deck Teardown: Leveraging Clinical Validation to Secure a $3M Seed Round
• AgomAb Therapeutics Pitch Deck Teardown: A Masterclass in Biotech Pipeline Visualization
• Buynomics Pitch Deck Teardown: A Data-Driven Case for Behavioral Pricing Intelligence
• EcoVadis Pitch Deck Teardown: A Masterclass in Growth-Stage Market Dominance
• HiBob Pitch Deck Teardown: A Narrative-Driven $150M Series D Masterclass
• Odeko Pitch Deck Teardown: A Masterclass in Obfuscating Real Traction Numbers
• Amogy Pitch Deck Teardown: Solving the Energy Density Gap for Heavy-Duty Mobility
• Circ Pitch Deck Teardown: Solving the Polycotton Recycling Gap with Hydrothermal Tech
• EVERY Pitch Deck Teardown: A $175M Masterclass in Precision Fermentation Storytelling
• Hourly Pitch Deck Teardown: Connecting Payroll Data to Real-Time Workers' Comp Premiums
• Moonlight Pitch Deck Teardown: A Community-First Approach to Remote Engineering
• Assembly Pitch Deck Teardown: A Product-First Series A Narrative Focused on Retention
• Comprehensive Pitch Deck Teardown: A Masterclass in Founder-Market Fit and Category Creation
• Florence Pitch Deck Teardown: Scaling a Healthcare Staffing Marketplace to £9bn Market Potential
• Innovafeed Pitch Deck Teardown: A $250M Masterclass in Industrial Scale and Strategic Partnerships
• Kinnu Pitch Deck Teardown: A Masterclass in Social Proof and Product-Led Growth
• Ben Pitch Deck Teardown: A $16M Series A Masterclass in Ecosystem Infrastructure
• Dalan Animal Health Pitch Deck Teardown: A $3.5M Seed for the First Honeybee Vaccine

Decks from the same year (1)

• 2021 pitch deck examples

Decks with a similar raise (1)

• Pitch decks that raised $50M to $250M

Browse companies alphabetically (1)

• Pitch decks from companies starting with A

More pitch deck teardowns (16)

• Aevus Pitch Deck Teardown: A $420k Seed Ask for Automated Diabetes Decision Support
• AFEX Integrated Solutions Pitch Deck Breakdown: The Slide Called "In Numbers" That Has No Numbers
• Affini-T Pitch Deck Breakdown: Engineering T Cells for Solid Tumors
• Affini-T Therapeutics Pitch Deck Teardown: A $175M Masterclass in Biotech Platform Credibility
• AfriBlock.io Pitch Deck Teardown: Building a Blockchain Education Ecosystem in Africa
• Afrocenchix Pitch Deck Breakdown: Dominating the $48B Afro Haircare Market with D2C Data
• Aftersale Pitch Deck Breakdown: A Masterclass in Traction-First Seed Fundraising
• Agave Games Pitch Deck Teardown: A $7M Seed Round Built on Mobile Gaming Pedigree
• Ageras Pitch Deck Teardown: A Multi-Product Ecosystem for SME Financial Services
• Ageras Group Pitch Deck Breakdown: The Ecosystem Play for SME Financial Services
• Ageras Pitch Deck Teardown: A Masterclass in Ecosystem Expansion and M&A Strategy
• AgFunder Pitch Deck Breakdown: A Minimalist Approach to Agriculture Capital Markets
• AgileRL Pitch Deck Teardown: Leveraging Open-Source Traction for a $7.5M Seed Round
• Agile Wash Pitch Deck Breakdown: Four Real Slides In A 37-Page Template
• Agility Health Pitch Deck Teardown: A Roll-Up Strategy in the Physical Therapy Market
• Golazzo$ Pitch Deck Teardown: Leveraging World Cup Momentum for Social Betting Expansion

Recently published pitch deck teardowns (12)

• Fuelfinance Pitch Deck Teardown: A $1M Seed Deck Built on Unit Economics and NPS
• Gendo Pitch Deck Teardown: A $1.1M Pre-Seed Bet on AI-Native Architectural Workflows
• Footprint Pitch Deck Teardown: The Hybrid Memo Strategy That Secured a $13M Series A
• Glystn Pitch Deck Teardown: Leveraging Founder Pedigree to Raise $4M for AI Creator Tools
• Green Li-ion Pitch Deck Teardown: A Masterclass in Supply Chain Disruption for Battery Recycling
• Halp Pitch Deck Teardown: A 7-Slide Memo Strategy for a $4M Seed Round
• Hangout Pitch Deck Teardown: Leveraging Music Licensing to Build a Social Goliath
• Goodword Pitch Deck Teardown: A $4M Seed Round Built on Founder Pedigree and AI Timing
• Hakio Pitch Deck Teardown: A 9-Slide Masterclass in Data-Driven Fashion Forecasting
• HealthCaters Pitch Deck Teardown: A B2B2C Play for Preventive Health Diagnostics
• HelloSky Pitch Deck Teardown: A Lean 8-Slide Case for AI-Driven Executive Search
• Heali Pitch Deck Teardown: Leveraging Clinical Validation to Secure a $3M Seed Round

Fundraising library · Pitch deck examples · Investor directory · Founder database